BACE1 and Alzheimer disease: For example, verubecestat, a BACE1 inhibitor, effectively suppressed production of Aβ in the AβPP proteolytic pathway and substantially cleared extracellular Aβ in AD patients, as reflected in the up to 80% reduction, in a dose-dependent manner, of the levels of Aβ in CSF [11,12].